Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
BOUNDLESS BIO INC (BOLD) Stock Price & Overview
NASDAQ:BOLD • US10170A1007
Current stock price
1.53 USD
+0.07 (+4.79%)
Last:
The current stock price of BOLD is 1.53 USD. Today BOLD is up by 4.79%. In the past month the price increased by 29.2%. In the past year, price decreased by -9.03%.
BOLD Key Statistics
52-Week Range0.9612 - 1.7249
Current BOLD stock price positioned within its 52-week range.
1-Month Range1.07 - 1.68
Current BOLD stock price positioned within its 1-month range.
- Market Cap
- 34.287M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.61
- Dividend Yield
- N/A
BOLD Stock Performance
Today
+4.79%
1 Week
-3.95%
1 Month
+29.20%
3 Months
+25.86%
Longer-term
6 Months +4.29%
1 Year -9.03%
2 Years -85.25%
3 Years N/A
5 Years N/A
10 Years N/A
BOLD Stock Chart
BOLD Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to BOLD. When comparing the yearly performance of all stocks, BOLD turns out to be only a medium performer in the overall market: it outperformed 55.25% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BOLD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BOLD. BOLD has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BOLD Earnings
Next Earnings DateMay 18, 2026
Last Earnings DateMar 9, 2026
PeriodQ4 / 2025
EPS Reported-$0.58
Revenue Reported
EPS Surprise -9.35%
Revenue Surprise %
BOLD Forecast & Estimates
7 analysts have analysed BOLD and the average price target is 4.08 USD. This implies a price increase of 166.67% is expected in the next year compared to the current price of 1.53.
Analysts
Analysts45.71
Price Target4.08 (166.67%)
EPS Next Y6.34%
Revenue Next YearN/A
BOLD Index Membership
BOLD is currently included in the following stock indexes tracked on ChartMill.
BOLD Financial Highlights
Over the last trailing twelve months BOLD reported a non-GAAP Earnings per Share(EPS) of -2.61. The EPS increased by 82.02% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-58.20M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.05% | ||
| ROE | -58.99% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%21.62%
Sales Q2Q%N/A
EPS 1Y (TTM)82.02%
Revenue 1Y (TTM)N/A
BOLD Ownership
Ownership
Inst Owners51.46%
Shares22.41M
Float19.86M
Ins Owners3.03%
Short Float %0.73%
Short Ratio0.64
BOLD Industry Overview
BOLD operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 23.0
- Average Fwd P/E
- 18.3
- Average Debt/Equity
- 2.2
BOLD Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.6 | 373.774B | ||
| AMGN | AMGEN INC | 13.86 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.95 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.82 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.75 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.61 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.042B | ||
| INCY | INCYTE CORP | 10.6 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BOLD
Company Profile
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
Company Info
IPO: 2024-03-28
BOUNDLESS BIO INC
10955 Alexandria Way, Suite 100
San Diego CALIFORNIA 94108 US
CEO: Matthew R. Patterson
Employees: 28
Phone: 18587669912
BOUNDLESS BIO INC / BOLD FAQ
What does BOLD do?
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2024-03-28. Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
What is the stock price of BOUNDLESS BIO INC today?
The current stock price of BOLD is 1.53 USD. The price increased by 4.79% in the last trading session.
Does BOUNDLESS BIO INC pay dividends?
BOLD does not pay a dividend.
What is the ChartMill technical and fundamental rating of BOLD stock?
BOLD has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy BOLD stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BOLD.
What is the employee count for BOLD stock?
BOUNDLESS BIO INC (BOLD) currently has 28 employees.